MedTrace Logo

Effects of Medications in Patients With Hypogonadism

NCT01601327 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 119

Last updated 2012-05-18

No results posted yet for this study

Summary

The aim of the present study was to demonstrate the influences of three different treatment strategies on biochemical parameters and testicular volume (TV) in patients with idiopathic hypogonadotropic hypogonadism (IHH).

Conditions

  • Idiopathic Hypogonadotropic Hypogonadism

Interventions

DRUG

Testosterone enanthate (Sustanon 250 mg)

Twenty-eight patients were treated with testosterone enanthate (TE),

DRUG

Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU)

twenty-five patients were treated with human chorionic gonadotropin (hCG)

DRUG

Testosteron gel (Testojel 50 mg)

Twenty-four patients were treated with testosterone gel (TG).

Sponsors & Collaborators

  • Gulhane School of Medicine

    lead OTHER

Principal Investigators

  • Aydogan Aydogdu, MD · Gulhane School of Medicine, Department of Endocrinology and Metabolism

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01601327 on ClinicalTrials.gov